BioLineRx Ltd. (BLRX.TA)
BioLineRx Ltd. operates in the Biotechnology industry of the Healthcare sector, headquartered in Modi'in, HM, IL. The stock last traded at $1.50, up 0.00% on the session, giving a market capitalisation of $39.2M. Its beta of 0.71 implies it has historically moved less than the broad market.
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
BioLineRx Ltd. is most often compared with the following Healthcare names: